How many drugs treat Bacterial meningitis?

Drug Landscape tracks 10 marketed treatments for Bacterial meningitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-meningitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial meningitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial meningitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Merrem	Meropenem	Pfizer	meropenem		1996-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Bacterial meningitis
Bristol-Myers Squibb · 2 drugs in Bacterial meningitis
Merck & Co. · 2 drugs in Bacterial meningitis
Pai Holdings Pharm · 2 drugs in Bacterial meningitis
National Institutes of Health Clinical Center (CC) · 1 drug in Bacterial meningitis
Novartis · 1 drug in Bacterial meningitis
Sterimax · 1 drug in Bacterial meningitis
Tel-Aviv Sourasky Medical Center · 1 drug in Bacterial meningitis
· 1 drug in Bacterial meningitis
University Hospital, Lille · 1 drug in Bacterial meningitis
Centre Hospitalier Universitaire Vaudois · 1 drug in Bacterial meningitis
GSK · 1 drug in Bacterial meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial meningitis:

Cite this brief

Drug Landscape (2026). Bacterial meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-meningitis. Accessed 2026-06-10.

Bacterial meningitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing